A new platform for research and industry collaborations in artificial intelligence

AI technology developers, pharmaceutical companies, and academic research groups form a platform for research and industry collaborations

WASHINGTON, DC, Sept 13th, 2018 - Pharmaceutical R&D efficiency has declined to a stall, as clinical trial failure rates for new drug IND's top out over 90%, and the cost to bring one new small molecule drug to market now exceeds $2.5 billion. In parallel, healthcare costs in developed countries are steadily increasing as a result of rapidly aging populations and multiple inefficiencies in the healthcare system. Recent advances in artificial intelligence research and development hold the potential to resolve these ominous trends. As a sign of the growing interest in AI based healthcare solutions, over 100 startup companies utilizing AI to develop biomedical products have emerged since 2014, with almost all existing large cap companies initiating AI development programs in order to keep up.

"We are on the cusp of major breakthroughs in the application of machine learning, computational science, and artificial intelligence, which carry the potential to dramatically improve the quality and affordability of healthcare globally and look forward to participation in AAIH as a mechanism to foster continued growth," says Brandon Allgood, CTO and Founder of Numerate Inc.

To accelerate the adoption of AI in healthcare, improve transparency and promote collaboration, leading members of the AI community have come together to collaborate and establish the Alliance for Artificial Intelligence in Healthcare (AAIH), an industry-wide research collaboration platform. The founding members of the Alliance for Artificial Intelligence in Healthcare (AAIH) met on September 6th during Boston Biotech Week (Boston, MA), and are meeting on September 13th during the Basel Life Congress (Basel, Switzerland) to finalize plans for the activities for the first 12 months of AAIH operations. The AAIH will officially launch in January 2019 during the week of the JP Morgan Healthcare Conference in San Francisco. The AAIH will foster research collaborations, improve data sharing, and promote key research results to accelerate biomedical research while implementing and adhering to high standards.

The potential of Artificial Intelligence to positively impact all aspects of healthcare has become an international discussion. The AAIH will be a key industry advocate, driving public policy, appropriate regulation, and market access for the products developed by the AI in healthcare industry. "If we are to build upon our recent industry success, and realize the true potential of AI, it is crucial that the sector organize immediately to enact policies and practices that will enable efficient adoption, integration, and commercialization," said Alex Zhavoronkov, CEO of Insilico Medicine.

The membership of AAIH includes the following areas of AI infrastructure and applications in healthcare: Biomedical discovery, Clinical Research, Diagnostics and Devices, and Precision Medicine. "It is the privilege of AAIH to unify and amplify the voice of companies and organizations from all sectors utilizing AI in healthcare," said Annastasiah Mhaka from Adjuvant Partners.
The list of AAIH Founding Members include:
AI Infrastructure developer (to be announced)
Benevolent AI
BlackThorn Therapeutics
The Buck Institute for Research on Aging
Cyclica
Envisagenics
BioPharma 1 (to be announced)
GE Healthcare
Insilico Medicine
BioPharma 2 (to be announced)
NuMedii
Numerate
OWKIN
Recursion
University of Pittsburgh
###
Media Contacts
Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
425-306-8716
Charles Craig
Opus Biotech Communications
Charles.s.craig@gmail.com
404-245-0591

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Montgomery County campus in Rockville, with R&D and management resources in Belgium, Hong Kong, Ukraine, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Insilico to present on human aging biomarker development at the BSRA Scientific Meeting

Thursday, the 30th of September, 2018, Rockville, MD - Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, is pleased to announce the talk of Polina Mamoshina, a senior research scientist at Insilico Medicine at the 68th British Society for Research on Ageing annual scientific meeting.

The BSRA meeting will take place at Oriel College, Oxford on the 6-8th September 2018. The BSRA is committed to funding, supporting and disseminating high-quality research into the biology of ageing. Support is available for active researchers with substantive posts at any UK institution or research institutes which are interested in the biology of ageing and who would normally be eligible for membership of the BSRA.

Polina Mamoshina's talk "Applications of deep neural networks to human ageing biomarker development" on the 8th of September, 2018 will be concentrated on using AI to identify useful, cheap and available biomarkers.

"I am really fascinated by the opportunity to present some of our recent research at one of the oldest Ageing Research Society annual meeting. At Insilico, we are working on comprehensive and robust biomarkers of ageing developed using deep learning and blood biochemistry, transcriptomics, and even imaging data to be able to track the effectiveness of the various interventions we are developing", said Polina Mamoshina, a senior research scientist at Insilico Medicine.

Associate Prof Lynne Cox, who is leading the cellular senescence and ageing research at the University of Oxford and co-organizing the BSRA meeting, noted: "I am delighted that Polina Mamoshina has agreed to speak at the upcoming British Society for Research on ageing annual scientific meeting that I am organising in Oxford from 6-8th September. The conference will address how current ageing research is leading to transformative treatments for age-related disease, and will include updates from exciting new clinical trials on novel anti-ageing drugs. Polina's use of AI to identify clinically useful biomarkers for ageing has huge potential in this context; such biomarkers are needed for diagnosis, prognosis and therapeutic monitoring of new anti-ageing treatments. Her contribution to the meeting will be greatly valued".

The work of Polina Mamoshina and colleagues at Insilico Medicine may help improve clinical trial enrollment practices, assess the population specificity of a variety of the biomarkers and pave the way for the development of more complex multi-modal biomarkers of aging and disease.
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
zhu@insilico.com
Website: http://www.insilico.com
Official Symposium Website:
http://www.africahealthbusiness.com
About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com